Abstract:Breast cancer is still the most common cancer among women worldwide, causing a heavy burden of disease, mortality and long-term survival. In this context, women's participation in breast cancer research, especially in the leadership process, is important for increasing knowledge and developing health policy. However, gender gaps in leadership still exist. According to the 2023 OCSE report, women make up less than 30% of scientists worldwide, and their representation in senior positions and as decision-makers is even lower, especially in programs such as medical and experimental oncology. This under-representation not only hinders development of new ideas to solve complex diseases, such as breast cancer, but also impedes the progress needed to solve the specific health problems faced by women.Negative factors such as research funding bias, organizational bias, and lack of continuing education risk hindering women's advancement in scientific research. Furthermore, as a result of their significant contributions to research, female researchers should be recognized more for their contributions, leadership, and talent in relevant publications. The COVID-19 pandemic has further exacerbated inequality, negatively impacting female researchers who face greater supervisory responsibilities, thereby reducing research output. As we strive for a more social environment, it is even more important to provide platforms that support and promote the work of female scientists.The Frontiers in Oncology's Women in Breast Cancer series provides one such platform to share the diverse, valuable latest contributions of female researchers to breast cancer research. Volume III contains 21 articles covering a wide range of topics from molecular analysis and new diagnostics to clinical and patient care. These projects are all led by women and include a large number of female scientists, at various stages in their careers. Collectively, this series provides insight into the evolution of breast cancer research, providing a deeper understanding of early treatment and the biological, psychological, and treatment of the disease.Advances in breast cancer diagnostics are critical to improving early diagnosis and ensuring that patients receive the best possible treatment and personalized care. A key study in this volume investigates the ability of ultrasound-based radiography to estimate the expression of important markers such as oestrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 in breast cancer patients (Xu et al.). This new approach aims to eliminate molecular testing, reduces the need for biopsies, and offers a more efficient, patient-friendly alternative to traditional diagnostics. These advances are particularly important for improving diagnostic accuracy and guiding treatment in different types of breast cancer.This research is complemented by another study on breast calcification, which is often an early sign of malignancy. A new machine learning algorithm was developed to improve the segmentation and quantification of calcium in mammograms (Tong et al.). The algorithm is superior in identifying microcalcifications compared to existing models, improving the diagnostic process by helping radiologists distinguish malignant diseases. This AI-powered innovation holds great promise for improving early detection and reducing misdiagnosis, especially in difficult-to-find early-stage breast tissue.Advances in decisive oncology continue to improve breast cancer treatment. Much of the research in this issue focuses on personalized treatment strategies to improve outcomes based on the patient's molecular profile. A key example is the study of the Lem-D protein in triple-negative breast cancer (TNBC) (Rose et al.). Because TNBC lacks hormone receptors that are frequently targeted by other types of breast cancer, treatments are often limited. The researchers in this volume describe the role of nuclear envelope proteins, such as Ankle2, TMPO, and Emerin in TNBC cell growth, providing compelling evidence that these proteins may serve as a new treatment plan. This opens the door to more effective, targeted interventions for one of the most serious and difficult-to-treat breast cancers.Improving of personalized therapy also include traditional treatment such as radiotherapy. Comparative studies of conventional and hypofractionated radiation therapy using the Halcyon system highlight the importance of radiation therapy to stabilize the tumour with reduced side effects (Tai et al.). The hypofractionation approach, which delivers more radiation in fewer sessions, has been shown to be better minimizing side effects, even if not as effective in controlling tumours, as than conventional ones.Breast cancer, irrespective of its extent and treatment, has negative impacts on several aspects of women's lives. This issue includes several studies that highlight the importance of health-related qual -Abstract Truncated-

Editorial for the Special Issue "Latest Review Papers in Molecular Oncology 2023"

Plenary Paper

Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics"

Editorial: The cross-talk between cancer cells and immune cells in the tumor microenvironment

Editorial for the Special Issue "Angiogenic Growth Factors in Tumor Development: Beyond New Blood Vessels Formation"

Special Issue "Molecular Advances in Cancer Genetics 3.0"

Editorial: Genetic and epigenetic regulation of stem cells by the immune system in homeostasis, regeneration, and oncogenesis.

Call for Special Issue Papers: Advances in Molecular Medicine

Editorial: Reviews in breast cancer: 2023

Editorial: Women in breast cancer, volume III: 2023

Editorial for the Special Issue “Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design”

Editorial for Special Issue "Brain Tumor Microenvironment"

Exploring the Role of Molecular Dynamics Simulations in Most Recent Cancer Research: Insights into Treatment Strategies

Special Issue "Cancer Biomarker Research and Personalized Medicine 2.0"

Editorial: Research progress on immune microenvironment and molecular mechanism of glioma

Editorial for the Special Issue "Advances in the Development of Anticancer Drugs"

Editorial: Colorectal cancer awareness month 2023: diagnosis, clinical course, and surgical management of metastatic colorectal cancer

The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives

Omics sciences and precision medicine in sarcoma

Editorial: Recent advances in Cancer biomarkers detection in biological samples

Editorial: Furthering precision medicine and cancer prevention through novel insights in molecular and chemical carcinogenesis